Q-omics provides the consensus-scored MDP1 profile across patient tissues and cancer cell-line models. MDP1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MDP1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MDP1 RNA expression shows 18,889 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, THCA, and ACC as cancer lineages where MDP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MDP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MDP1 survival associations across molecular data types. MDP1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MDP1 RNA expression–survival associations across cancer types. High MDP1 expression shows unfavorable associations in UVM, MESO, KICH and HNSC, but favorable associations in BRCA and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MDP1 RNA expression.
This table summarizes MDP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MDP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MDP1 shows lower tumor expression in THCA, LUAD and KICH and higher tumor expression in CHOL, LIHC and ESCA. The THCA box plot shows higher MDP1 RNA expression in normal versus tumor tissue (log2 FC = −0.685, t-test p < 0.001).
This table shows molecular features associated with MDP1 in patient tissues and cancer cell lines. In patient samples, MDP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MDP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
